Research ArticleCancer

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

See allHide authors and affiliations

Science Translational Medicine  28 Jan 2015:
Vol. 7, Issue 272, pp. 272ra12
DOI: 10.1126/scitranslmed.3010445

Log in to view Figures & Data

Log in through your institution

Log in through your institution

Stay Connected to Science Translational Medicine